Nanobiotix S.A. (NBTX)
$23.40-1.18%Close
SELLCRISIS · day 29
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.2B
- Beta
- 0.57
- P/E (TTM)
- -17.90
- Short % float
- 0.36%
- Days to cover
- 1.0
- SI change
- -16.6%
- 1W
- -6.77%
- 1M
- -36.77%
- vs SPY 1W
- -7.19%
- vs SPY 1M
- -38.83%
Industry peers
FMP comparable companies · ranked by market cap
- IBRXBUYImmunityBio, Inc.$10.3BRECOVERYQ 8$9.80-3.71%
- SNDXSELLSyndax Pharmaceuticals, Inc.$1.2BCRISISQ 16$13.95-2.59%
- TYRASELLTyra Biosciences, Inc.$1.1BCRISISQ 5$18.56-1.71%
- KURASELLKura Oncology, Inc.$873MBEARQ 12$9.83-1.89%
- AVBPSELLArriVent BioPharma, Inc.$749MCRISISQ -6$16.09-1.61%
- CADLSELLCandel Therapeutics, Inc.$679MCRISISQ 18$9.27-1.61%
- PBYIBUYPuma Biotechnology, Inc.$515MBULLQ 13$10.12+0.00%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on NBTX?
- LOPJLB’s latest quantitative signal on Nanobiotix S.A. (NBTX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is NBTX in?
- Nanobiotix S.A. (NBTX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Nanobiotix S.A. (NBTX) do?
- Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma…